207 related articles for article (PubMed ID: 32630529)
1. Prolyl Endopeptidase-Like Facilitates the α-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF.
Santos GS; Oyadomari WY; Carvalho EA; Torquato RS; Oliveira V
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32630529
[TBL] [Abstract][Full Text] [Related]
2. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
5. Glycosaminoglycans have variable effects on α-synuclein aggregation and differentially affect the activities of the resulting amyloid fibrils.
Mehra S; Ghosh D; Kumar R; Mondal M; Gadhe LG; Das S; Anoop A; Jha NN; Jacob RS; Chatterjee D; Ray S; Singh N; Kumar A; Maji SK
J Biol Chem; 2018 Aug; 293(34):12975-12991. PubMed ID: 29959225
[TBL] [Abstract][Full Text] [Related]
6. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
Singh P; Bhat R
ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
[TBL] [Abstract][Full Text] [Related]
7. Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors.
Jha NN; Kumar R; Panigrahi R; Navalkar A; Ghosh D; Sahay S; Mondal M; Kumar A; Maji SK
ACS Chem Neurosci; 2017 Dec; 8(12):2722-2733. PubMed ID: 28872299
[TBL] [Abstract][Full Text] [Related]
8. Complexation of NAC-Derived Peptide Ligands with the C-Terminus of α-Synuclein Accelerates Its Aggregation.
Jha NN; Ranganathan S; Kumar R; Mehra S; Panigrahi R; Navalkar A; Ghosh D; Kumar A; Padinhateeri R; Maji SK
Biochemistry; 2018 Feb; 57(5):791-804. PubMed ID: 29286644
[TBL] [Abstract][Full Text] [Related]
9. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
[TBL] [Abstract][Full Text] [Related]
10. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
11. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
12. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein.
Sengupta U; Puangmalai N; Bhatt N; Garcia S; Zhao Y; Kayed R
Mol Neurobiol; 2020 Jun; 57(6):2741-2765. PubMed ID: 32350746
[TBL] [Abstract][Full Text] [Related]
14. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of synucleinopathic seeding by rationally designed inhibitors.
Sangwan S; Sahay S; Murray KA; Morgan S; Guenther EL; Jiang L; Williams CK; Vinters HV; Goedert M; Eisenberg DS
Elife; 2020 Jan; 9():. PubMed ID: 31895037
[TBL] [Abstract][Full Text] [Related]
16. Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein.
Xu MM; Ryan P; Rudrawar S; Quinn RJ; Zhang HY; Mellick GD
Acta Pharmacol Sin; 2020 Apr; 41(4):483-498. PubMed ID: 31586134
[TBL] [Abstract][Full Text] [Related]
17. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
18. α-synuclein aggregation and its modulation.
Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
[TBL] [Abstract][Full Text] [Related]
19. The conformation and the aggregation kinetics of α-synuclein depend on the proline residues in its C-terminal region.
Meuvis J; Gerard M; Desender L; Baekelandt V; Engelborghs Y
Biochemistry; 2010 Nov; 49(43):9345-52. PubMed ID: 20828147
[TBL] [Abstract][Full Text] [Related]
20. Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human α-, β-, and γ-Synuclein Proteins.
Jain MK; Singh P; Roy S; Bhat R
Biochemistry; 2018 Jul; 57(26):3830-3848. PubMed ID: 29851342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
